Cellectis S Clause Samples
Cellectis S. A., a public limited liability company (société anonyme) incorporated in France under number 428 859 052 RCS Paris, having its registered office at 8 ▇▇▇ ▇▇ ▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇, Paris, France (the "Issuer" or the "Company"), represented by A▇▇▇▇ ▇▇▇▇▇▇▇▇, duly authorised for the purpose hereof. The Subscriber and the Issuer are hereinafter referred to, collectively, as the "Parties" and, individually, as a "Party".
Cellectis S. A. retains rights under the Cellectis Patents and is not restricted from granting rights to Third Parties under the Cellectis Patents, (b) any licenses and rights granted by Precision to Baxalta under the Cellectis Patents are granted only within the permissible scope of sublicenses granted under the Cellectis Agreement, and (c) pursuant to the Cellectis Agreement, Cellectis S.A. retains non-exclusive rights under certain Precision Patents and Precision Platform Patents identified in the Cellectis Agreement, which may be further sublicensed by Cellectis S.A. without Precision control or consent. Baxalta acknowledges and [***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. agrees that any exercise of any right by Cellectis S.A, or by any Third Party through Cellectis S.A, under the Cellectis Agreement shall not constitute a breach of this Agreement by Precision. Each Party shall not, and shall not permit any of its Affiliates or sublicensees to, practice any Patent Rights or Know-How licensed to it by the other Party outside the scope of the license granted to it under this Agreement.
Cellectis S. A. Re. Letter-Agreement related to the investment of AstraZeneca into Cellectis S.A.1
Cellectis S. A., a Corporation under the laws of France having a place of business at ▇, ▇▇▇ ▇▇ ▇▇ ▇▇▇▇▇ ▇▇▇▇▇, 75013 Paris, France (“Cellectis”) is dated as of the date on which the last Party executes this Amendment. Notwithstanding the Amendment Effective Date, the Parties hereby agree that the provisions of this Amendment shall be deemed to have taken effect as of the seventeenth (17th) day of November 2025 (the “Amendment Effective Date”).
Cellectis S. A. may exercise its Option to Sublet by providing Landlord with written notice within fifteen (15) days of Tenant’s receipt of a notice of Default.